Mitchell S von Itzstein
Overview
Explore the profile of Mitchell S von Itzstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Itzstein M, Burns T, Dowell J, Horn L, Camidge D, York S, et al.
Clin Cancer Res
. 2024 Dec;
31(4):639-648.
PMID: 39651955
Purpose: Patients with Kirsten rat sarcoma viral oncogene (KRAS)-mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on the activity of nuclear export inhibition in preclinical models, we...
2.
von Itzstein M, Liu J, Mu-Mosley H, Fattah F, Park J, Sorelle J, et al.
JTO Clin Res Rep
. 2024 Dec;
6(1):100751.
PMID: 39619775
Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in...
3.
Narra K, Ghabach B, Athipatla V, Blackwell J, Teigen K, Bullock J, et al.
Clin Lung Cancer
. 2024 Sep;
26(2):83-92.
PMID: 39304363
Introduction: Advances in the testing and treatment of patients with non-small cell lung cancer (NSCLC) harboring oncogenic drivers have improved outcomes. Little is known about testing and treatment patterns in...
4.
von Itzstein M, Gerber D, Bermas B, Meara A
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39038920
Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their success is mitigated by the recognition that ICI-induced immune-related adverse events (irAEs) pose considerable challenges to patients and clinicians. These...
5.
Song B, Wang K, Na S, Yao J, Fattah F, von Itzstein M, et al.
bioRxiv
. 2024 Jul;
PMID: 39005456
The interaction between antigens and antibodies (B cell receptors, BCRs) is the key step underlying the function of the humoral immune system in various biological contexts. The capability to profile...
6.
von Itzstein M, Liu J, Mu-Mosley H, Fattah F, Park J, Sorelle J, et al.
bioRxiv
. 2024 Jun;
PMID: 38915535
Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in...
7.
Burnette H, Pabani A, von Itzstein M, Switzer B, Fan R, Ye F, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816231
Background: Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding...
8.
Mu-Mosley H, von Itzstein M, Fattah F, Liu J, Zhu C, Xie Y, et al.
Oncoimmunology
. 2024 May;
13(1):2351255.
PMID: 38737792
Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial...
9.
von Itzstein M, Yang Y, Wang Y, Hsiehchen D, Sheffield T, Fattah F, et al.
Front Immunol
. 2024 May;
15:1351739.
PMID: 38690281
Background: A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of...
10.